

EOSINOPHILIC ESOPHAGITIS: FREQUENTLY ASKED QUESTIONS



What is eosinophilic esophagitis (EoE)?

EoE is a chronic, progressive, inflammatory disease characterized by symptoms related to esophageal dysfunction and Type 2 inflammation driven by T helper 2 (Th2)-type responses.¹⁻³ EoE can lead to a variety of symptoms, including^{2,4-8}:

- Dysphagia
- Chest pain (noncardiac)
- Fibrosis of the esophagus
- Food impaction requiring bolus removal
- Impaired quality of life (eg, social isolation, higher economic burden)

People living with EoE often require significant lifestyle modifications to reduce symptoms.^{4,8} Approximately 1 in 2000 people have EoE in the United States, and diagnosis in adults can be delayed by ~10 years due to misdiagnosis or underdiagnosis.^{9,10}



What type of inflammation drives EoE?

EoE is driven primarily by chronic Type 2 inflammation, characterized by epithelial barrier dysfunction, immune dysregulation, and enhanced Th2 cell activity.^{2,11,12} Esophageal biopsies and blood samples of patients with active EoE show increased levels of hallmark Type 2 cytokines and chemokines. Type 2 inflammation in EoE encompasses^{11,13}:

INFLAMMATORY CELL TYPES

- Th2 cells
- ILC2 cells
- Mast cells
- Basophils
- Eosinophils
- B cells

KEY TYPE 2 CYTOKINES

- IL-4
- IL-13
- IL-5

ILC2, type 2 innate lymphoid cells.



Does Type 2 inflammation drive any other diseases?

Yes. Chronic Type 2 inflammation can be a feature of certain allergic diseases, such as allergic rhinitis, asthma, atopic dermatitis, CRSwNP, food allergy, and a range of other inflammatory diseases.¹³

In all of these diseases, Type 2 inflammation can play a central role in pathogenesis and is associated with the key cytokine mediators IL-4, IL-13, and IL-5.¹³

**~75% of patients with EoE have at least 1 additional
Type 2 inflammatory disease^{10,13-16}**

CRSwNP, chronic rhinosinusitis with nasal polyposis.



What is the impact of Type 2 inflammation on EoE?

Chronic Type 2 inflammation in EoE results in histologic and endoscopic changes that reflect symptom progression^{6,11-13,17-22}:

B-CELL CLASS SWITCHING

IL-4 and IL-13 promote B-cell class switching and production of IgE and IgG4

MAST CELL AND BASOPHIL ACTIVATION

IL-4 and IL-13 contribute to the activation of mast cells and basophils, leading to degranulation of several inflammatory mediators

EPITHELIAL BARRIER DYSFUNCTION

IL-4 and IL-13 increase epithelial permeability and promote barrier disruption, leading to increased exposure to allergens and pathogens and leukocyte infiltration

REMODELING AND FIBROSIS

IL-13 contributes to tissue remodeling and fibrosis (such as furrows, rings, and strictures) and increased smooth muscle contraction

EOSINOPHILIC INFLAMMATION

IL-4, IL-13, and IL-5 promote eosinophil trafficking to tissues through chemoattractants, contributing to esophageal remodeling, and IL-5 induces eosinophil differentiation in the bone marrow and extravasation into the bloodstream



How does chronic inflammation remodel the esophagus over time in EoE?

EoE is a progressive disease characterized by histologic and endoscopic changes to the esophagus due to chronic Type 2 inflammation.^{1,3,11,13,23-25}

Key Type 2 inflammatory mediators IL-4, IL-13, and IL-5 can propagate local inflammation, resulting in esophageal remodeling and fibrosis.^{11,13} Endoscopic findings may include²³:

SIGNS OF INFLAMMATION

- Furrows/ridges
- White exudates
- Pale, edematous mucosa, decreased vascularity
- Fragile mucosa: crêpe paper esophagus, with lacerations at the passage of the endoscope

SIGNS OF FIBROSTENOSIS

- Esophageal rings or diffuse esophageal stenosis, narrow-caliber esophagus
- Fixed esophageal rings (trachealization)
- Feline esophagus

Progressive remodeling and fibrosis may lead to esophageal strictures and worsen dysphagia. This may result in food impaction requiring dilation¹



How is EoE currently managed?

Current EoE management approaches include^{6,7,23-26}:

- Food elimination diets
- Cycles of swallowed TCS
- PPIs
- Esophageal dilation
- Upper endoscopy for the management of esophageal food impaction

Current standards of care may not fully address the underlying Type 2 inflammation in EoE.^{2,6,25,26} There remains an unmet need to reduce esophageal dysfunction and the underlying Type 2 inflammation to improve endoscopic signs, clinical symptoms, and quality of life in patients with EoE.²⁵

PPI, proton pump inhibitor; TCS, topical corticosteroid.



What is the goal of disease management in EoE?

The goal of EoE management is to achieve multiple measures of disease remission^{27,28}:

- Clinical remission, characterized by lack or reduction of EoE-attributed symptoms
- Endoscopic remission, characterized by absence of inflammatory signs (eg, white exudates, furrows, edema), EREFS score ≤ 2
- Histological inflammatory remission, characterized by peak eosinophil count ≤ 6 EOS/HPF histology/HE stain

EOS, eosinophils; EREFS, endoscopic reference score; HE, hematoxylin and eosin; HPF, high-power field.

References: 1. Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. *Gastroenterology*. 2018;154(2):319-332.e3. 2. O'Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of eosinophilic esophagitis. *Gastroenterology*. 2018;154(2):333-345. 3. Shaheen NJ, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk GW. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. *Dis Esophagus*. 2018;31(8):doy015. 4. Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health-related quality of life and costs associated with eosinophilic esophagitis: a systematic review. *Clin Gastroenterol Hepatol*. 2018;16(4):495-503.e8. 5. Li-Kim-Moy JP, Tobias V, Day AS, Leach S, Lemberg DA. Esophageal subepithelial fibrosis and hyalinization are features of eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr*. 2011;52(2):147-153. 6. D'Alessandro A, Esposito D, Pesce M, Cuomo R, De Palma GD, Sarnelli G. Eosinophilic esophagitis: from pathophysiology to treatment. *World J Gastrointest Pathophysiol*. 2015;6(4):150-158. 7. Straumann A, Bussmann C, Zuber M, Vannini S, Simon H-U, Schoepfer A. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. *Clin Gastroenterol Hepatol*. 2008;6(5):598-600. 8. Pokrzywinski RM, Harding G, Brooks A, Goodwin B, Williams J. Documenting the journey of patients with eosinophilic esophagitis and the impact of the disease on patients and their caregivers: a cross-sectional, qualitative research study. *Adv Ther*. 2020;37(10):4458-4478. 9. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. *Clin Gastroenterol Hepatol*. 2014;12(4):589-596.e1. 10. Chehade M, Jones SM, Pesek RD, et al. Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the Consortium for Food Allergy Research. *J Allergy Clin Immunol Pract*. 2018;6(5):1534-1544.e5. 11. Hill DA, Spergel JM. The immunologic mechanisms of eosinophilic esophagitis. *Curr Allergy Asthma Rep*. 2016;16(2):9. 12. Gómez-Aldana A, Jaramillo-Santos M, Delgado A, Jaramillo C, Lúquez-Mindiola A. Eosinophilic esophagitis: current concepts in diagnosis and treatment. *World J Gastroenterol*. 2019;25(32):4598-4613. 13. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov*. 2016;15(1):35-50. 14. van Rhijn BD, Bredenoord AJ. Management of eosinophilic esophagitis based on pathophysiological evidence. *J Clin Gastroenterol*. 2017;51(8):659-668. 15. Jyonouchi S, Brown-Whitehorn TA, Spergel JM. Association of eosinophilic gastrointestinal disorders with other atopic disorders. *Immunol Allergy Clin North Am*. 2009;29(1):85-97. 16. Padia R, Curtin K, Peterson K, Orlandi RR, Alt J. Eosinophilic esophagitis strongly linked to chronic rhinosinusitis. *Laryngoscope*. 2016;126(6):1279-1283. 17. Furuta GT, Katzka DA. Eosinophilic esophagitis. *N Engl J Med*. 2015;373(17):1640-1648. 18. Davis BP, Rothenberg ME. Mechanisms of disease of eosinophilic esophagitis. *Annu Rev Pathol*. 2016;11:365-393. 19. Malhotra N, Levine J. Eosinophilic esophagitis: an autoimmune esophageal disorder. *Curr Probl Pediatr Adolesc Health Care*. 2014;44(11):335-340. 20. Siracusa MC, Kim BS, Spergel JM, Artis D. Basophils and allergic inflammation. *J Allergy Clin Immunol*. 2013;132(4):789-801. 21. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. *Clin Exp Allergy*. 2017;47(2):161-175. 22. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. *Proc Natl Acad Sci U S A*. 1993;90(8):3730-3734. 23. Gomez Torrijos E, Gonzalez-Mendiola R, Alvarado M, et al. Eosinophilic esophagitis: review and update. *Front Med (Lausanne)*. 2018;5:247. 24. Bolton SM, Kagalwalla AF, Wechsler JB. Eosinophilic esophagitis in children: endoscopic findings at diagnosis and post-intervention. *Curr Gastroenterol Rep*. 2018;20(1):4. 25. Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. *United European Gastroenterol J*. 2017;5(3):335-358. 26. Wolf WA, Dellon ES. Eosinophilic esophagitis and proton pump inhibitors: controversies and implications for clinical practice. *Gastroenterol Hepatol (N Y)*. 2014;10(7):427-432. 27. Safroneeva E, Straumann A, Coslovsky M, et al; International Eosinophilic Esophagitis Activity Index Study Group. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. *Gastroenterology*. 2016;150(3):581-590.e4. 28. Ma C, Schoepfer AM, Dellon ES, et al; The COREOS Collaborators. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). *J Allergy Clin Immunol*. Accepted manuscript. Published online July 6, 2021. doi.org/10.1016/j.jaci.2021.07.001